Board Meeting held on August 14, 2026 for the quarter ended June 30, 2026.

Date: 14th August, 2026 Department of Corporate Services (DSC-CRD) Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001 Subject: Outcome of Board Meeting held on Friday, 14th August, 2026 pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Scrip Code: 524414 Dear Sir, With reference to above captioned subject and in continuation to the intimation letter dated August 08, 2026, we wish to inform you that, the meeting of the Board of Directors of Norris Medicines Limited (“the Company”) held today, i.e., Friday, August 14, 2026 inter alia considered and approved the following: 1. Un-Audited Financial Results of the Company for the Quarter ended June 30, 2026 along with Limited Review Report of the Statutory Auditors on the said Un-audited Financial Results of the Company pursuant to Regulation 30 and 33 of the SEBI (LODR) Regulations, 2015, are enclosed herewith Annexure A; We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations. 2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as a Managing Director (Promoter and Executive) of the Company for a term of 3 (Three) consecutive years effective from September 01, 2026 till August 31, 2029 (both days inclusive), be liable to retire by rotation. The said re- appointment is subject to the approval of the Shareholders of the Company. Mr. Vimal Dhirendra Shah (DIN: 01506655) is not disqualified from being appointed as a Managing Director in terms of the Companies Act 2013 and has given his consent to act as a Managing Director. The details required under Regulation 30 of the Listing Regulations read with applicable SEBI Circular(s) in respect of appointment of KMP, are enclosed herewith as Annexure B. Board meeting’s commencement time: 03:00 PM Board meeting’s concluded time: 04:00 PM Kindly take the same on your record and acknowledge receipt of the same. Thanking you. FOR NORRIS MEDICINES LIMITED VIMAL D. SHAH DIRECTOR DIN-01506655 Annexure B Details with respect to Regulation 30 read with Schedule Ill of the Listing Regulations, SEBI Circular SEBI Circular bearing Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Name of the Managing Director Mr. Vimal Dhirendra Shah (DIN: 01506655) Reason for change Viz appointment, Appointment as Managing Director of the Resignation, removal, death or otherwise Company for a term of 3 years with effect from September 1, 2026, be liable for Retire by Rotation. Date of Appointment /re- Appointment is with effect from 01st appointment/cessation (as applicable) & September, 2026. term of appointment/re-appointment Brief profile (In case of appointment) He is a Commerce graduate with more than 15 years of experience in Business Management. He has extensive experience in managing and overseeing business operations and contributing to the overall growth and development of the Company. He is a member of the Audit Committee and the Stakeholders Relationship Committee of the Company. In view of his experience and knowledge of the business, he is proposed to be appointed as the Managing Director of the Company for the prescribed term. Disclosure of relationship between He is not related to any of the Directors and Directors (in case of appointment) Key Managerial Personnel of the Company. Confirmation in compliance with SEBI NA. Letter dated June 14, 2018 read along with Exchange Circular dated June 20, 2018 (Affirmation that the person proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority) Affirmation that the Director being NA. appointed is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013 FOR NORRIS MEDICINES LIMITED VIMAL D. SHAH DIRECTOR DIN-01506655